Abstract
Type 2 diabetes mellitus is closely linked with cardiovascular diseases.Successful management of type 2 diabetes mellitus requires effective and safe control of glycemia.as well as comprehensive intervention of other risk factors,such as hypertension and overweight,to effectively reduce the occurrence of diabetic macrovascular complications.FDA also stressed the need to evaluate cardiovascular safety of new hypoglycemic drugs.The recent evidence suggests glucagons-like peptide-1(GLP-1)may address many of the needs of diabetes treatment such as glucose concentration-dependent hypoglycemic and β-cell protection,low risk of hypoglycemia,weight loss,and unique cardiovascular protection.Liraglutide is one of human GLP-1 analogues with high homology to the native hormone.A comprehensive phase Ⅲ(Liraglutide Effect and Action in Diabetes,LEAD)program showed that once-daily liraglutide significantly improved glucose control with low rates of hypoglycemia occurrence.Additional beneficial effects of liraglutide on body weight,systolic blood pressure,and other cardiovascular benefits were also documented,suggesting the unique advantages of GLP-1 analogue in cardiovascular disease risk prevention. Key words: Diabetes mellitus,type 2; Cardiovascular diseases; Glucagons-like peptide-1; Liraglutide
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
